46 results about "Methane sulfonate" patented technology

The embodiment of the invention provides a method for regulating and controlling the form of ginseng adventitious roots and saponin accumulation. The method comprises the following steps: (a) carrying out mutagenesis treatment on initial ginseng adventitious roots by using ethyl methane sulfonate (EMS); (b) performing multiple rounds of screening and subculture to obtain to-be-selected ginseng adventitious roots with different forms and saponin accumulation; and (c) determining one or more target genes for regulating and controlling the form of the ginseng adventitious root and saponin accumulation based on the ginseng adventitious root to be selected.

The present invention relates to the field of pharmaceutical chemistry, and discloses a salt of carebastine and its use, which solves the problems of the prior art, such as poor solid form of carebastine, many impurities, instability, difficulty in purification, difficulty in mass synthesis, and inapplicability to medicinal use. The salt of carebastine of the present invention includes, but is not limited to, acid salts or base salts, particularly potassium salt, sodium salt, methanesulfonate salt and p-toluenesulfonate salt. The salt of carebastine of the present invention is used in the preparation of drugs for histamine H1 receptor antagonists. The salt of carebastine of the present invention has the characteristics of easy purification, high stability, simple process, easy industrial production, and good hygroscopicity and convenient storage. And the salt of the present invention can enter the body quickly and exert its medicinal effect, has good oral absorption, and is superior to ebastine in both safety and individual variation, and is a promising anti-allergic disease drug for development.

The invention discloses a lactococcus lactis strain with high nisin yield and application, and belongs to the technical field of industrial microorganisms. According to the invention, a nisin-tolerant nisin high-producing strain (Lactococcus lactis MN6) is successfully bred on the basis of compound mutation of ethyl methane sulfonate and heavy ion beam and in combination with nisin resistance screening, the strain can tolerate a fermentation environment with the nisin concentration of 6000 IU. ML <-1 >, the nisin yield through shake flask horizontal fermentation can reach 10776 IU. ML <-1 >, which is 9.76 times of the shake flask fermentation yield of original bacteria, the strain has good passage stability, and the strain can be used for producing a high-yield strain of nisin. The method is more suitable for industrial production.

The use of a compound of formula (I) to treat adiposity, obesity, and diabetes is disclosed. Compositions comprising the methanesulfonate salt are disclosed as being particularly well-suited for oral administration.

The invention provides a preparation method of a key intermediate (3aR, 5S, 6aS)-5-(methylamino) hexahydrocyclopenta [c] pyrrol-2 (1H)-tert-butyl formate mesylate of a JAK kinase inhibitor, and belongs to the field of medical intermediates. The preparation method comprises the following steps: taking cis-5-oxohexahydrocyclopenta [C] pyrrol-2 (1H)-carboxylic acid tert-butyl ester as a raw material to react with methylamine equivalent to obtain an intermediate A; then carrying out reduction reaction in metal sodium and isopropanol to obtain a crude product, adding L-DBTA to form salt, removing isomers, and carrying out re-dissociation and salt formation with methanesulfonic acid to obtain a pure product. The method greatly shortens the reaction steps, reduces the raw material cost, is simple and reliable in process, and is easy for industrial production.

The invention discloses an antibacterial bamboo fiber for traceless underwear and a preparation method of the antibacterial bamboo fiber, and relates to the technical field of textile fibers. When the antibacterial bamboo fiber for the traceless underwear is prepared, bamboo pulp reacts with 3-aminopropyltrimethoxysilane to prepare modified bamboo pulp; the preparation method comprises the following steps: copolymerizing acrylonitrile and dibutyl (allyl) phosphine to prepare pre-modified polyacrylonitrile; enabling the pre-modified polyacrylonitrile to react with pyrimidine-2-yl methyl methanesulfonate, so as to obtain modified polyacrylonitrile; the modified polyacrylonitrile and the modified bamboo pulp are mixed and then subjected to wet spinning, then the mixture is immersed in deionized water, and polyacrylonitrile modified bamboo fibers are prepared; and immersing the polyacrylonitrile modified bamboo fiber into a silver plating solution to prepare the antibacterial bamboo fiber for the traceless underwear. The antibacterial bamboo fiber for traceless underwear prepared by the invention has good antibacterial, flame-retardant and moisture-absorbing properties.

The present invention relates to the field of medical intermediates, and provides a preparation method for a key intermediate tert-butyl (3aR,5S,6aS)-5-(methylamino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate mesylate of a JAK kinase inhibitor. The method comprises: reacting tert-butyl cis-5-oxohexahydrocyclopenta[C]pyrrole-2(1H)-carboxylate as a raw material with a methylamine equivalent to obtain intermediate A; and then carrying out a reduction reaction in metallic sodium and isopropanol to obtain a crude product, adding L-DBTA to form a salt, removing isomers, and then carrying out re-liberation and salt formation with methanesulfonic acid to obtain a purified product. The method significantly reduces reaction steps, reduces raw material costs, has a simple and reliable process, and is easy for industrial production.

An Aspergillus niger mutant strain designated MTCC 25759 derived from parent strain Aspergillus niger ATCC 9142 through chemical mutagenesis using ethyl methane sulfonate at 1 mg / mL for 30 to 60 minutes demonstrates enhanced production capabilities for both citric acid and gluconic acid. The mutant strain exhibits genetic modifications at 47 specific sequence positions that contribute to improved metabolic pathways, enhanced substrate utilization efficiency, and increased tolerance to acidic fermentation conditions. The mutant strain achieves gluconic acid production of 198.836 g / L representing a 66% improvement over the parent strain's 119.776 g / L yield, and citric acid production reaching 0.415 g / L with consistent late-phase productivity. The enhanced production capabilities provide economic advantages through improved substrate conversion rates, reduced raw material costs, and increased production capacity within existing fermentation infrastructure while maintaining the Generally Regarded As Safe (GRAS) status for commercial applications.

Disclosed in the present invention are a salt of a nicotinate compound, a crystal of the salt, and a preparation method therefor and a use thereof. The salt is selected from benzenesulfonate, phosphate, sulfate, hydrochloride, and methanesulfonate of a compound represented by formula (I). The crystal is crystal form A of the benzenesulfonate of the compound represented by formula (I), crystal form B of the benzenesulfonate of the compound represented by formula (I), crystal form A of the phosphate of the compound represented by formula (I), crystal form A of the sulfate of the compound represented by formula (I), crystal form A of the hydrochloride of the compound represented by formula (I), crystal form A of the methanesulfonate of the compound represented by formula (I), crystal form B of the methanesulfonate of the compound represented by formula (I), or an amorphous form of the methanesulfonate of the compound represented by formula (I).

The present invention relates to a pharmaceutically acceptable salt of a sphingosine-1-phosphate receptor agonist and a crystalline form thereof, and more specifically, to a potassium salt or methanesulfonate of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid of formula 1, and a crystalline form thereof.

The present invention refers to three new polymorphic forms of phentolamine mesylate and to the processes for their production.

The present invention is related to methods of treating cardiac arrhythmia, angina, or a migraine in a patient in need thereof, with a therapeutically effective amount of a compound having a structure according to the formula:the method comprising nasally administering to the patient (i) a first dose, and (ii) a second dose of an aqueous composition comprising a pharmaceutically acceptable acetate or methanesulfonate salt of compound I, or a racemate or enantiomer thereof, wherein the acetate or methanesulfonate salt of compound I, or the racemate or enantiomer thereof, is dissolved in the aqueous composition at a concentration of 350 mg / mL±50 mg / mL, and wherein the second dose of the compound is administered between 5 minutes and 25 minutes after the first dose.

To provide a method for efficiently producing graphene precursor and graphene in a short time.SOLUTION: A graphene precursor is synthesized by applying electric currents to an electrochemical reaction system including a cathode which includes graphite, an anode which may include graphite, and an electrolyte solution which includes a salt of trifluoromethanesulfonic acid or a salt of methanesulfonic acid as an electrolyte. The obtained graphene precursor is heated to obtain graphene.SELECTED DRAWING: Figure 1

Provided herein are novel polymorphic forms of metopimazine methanesulfonate. These polymorphic forms are useful in methods, compositions, and kits for treating enteric nervous system disorders.

The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

This invention belongs to the field of environmental protection technology, and provides a composite particle for treating floating algae in water bodies, its preparation method, and its application. The preparation method includes the following steps: a) preparing core-active Gemini-type bisquaternary ammonium cationic polymer methanesulfonate; b) preparing a coating material; c) preparing composite particles: mixing the coating material from step b with castor oil and sodium bicarbonate, heating and stirring to obtain a coating solution, adding the Gemini-type bisquaternary ammonium cationic polymer methanesulfonate prepared in step a, and obtaining composite particles; d) evaluating the performance of the composite particles. This invention uses a biodegradable and non-toxic natural polymer material as an outer coating to achieve the slow release and targeted release of quaternary ammonium salts. By coating quaternary ammonium salts in a complex formed by PVA and chitosan, controlling its release rate, and adjusting density to achieve floating or suspension, targeted treatment of cyanobacteria on the water surface is achieved.

The invention discloses a method for innocent treatment of household garbage incineration fly ash, which comprises the following steps: (1) fly ash pretreatment: taking household garbage incineration fly ash as a raw material, and drying to obtain a pretreated fly ash raw material; (2) preparation of a methanesulfonic acid-iron methanesulfonate extracting solution: firstly adding lead oxide into a methanesulfonic acid solution to form lead methanesulfonate, then adding ferric sulfate to mutually convert soluble salts into iron methanesulfonate and precipitate lead sulfate, and taking the light pink supernatant as an extraction stock solution which is a methanesulfonic acid-iron methanesulfonate stock solution; and (3) metal extraction and dechlorination are conducted, specifically, the fly ash raw material and the methanesulfonic acid-iron methanoate solution are mixed to react, and after the reaction is completed, a leaching solution is obtained through filtering. According to the invention, the use of chemical agents is effectively reduced, and the energy consumption is low. And the obtained leachate is subjected to subsequent treatment, so that a methanesulfonic acid-iron methanoate solution can be reused for metal leaching and dechlorination steps, and the whole method is more green and feasible.

A polymer having the structure N+ Ar is a N-containing monocyclic or bicyclic aromatic ring having 1 or 2 N atoms, at least one of the N atoms is substituted with Ra to have a positive charge and the ring is optionally substituted with Rb, Ra is H, thiophene, furan, pyridine, benzene, thiazole, C1-C12 alkyl optionally substituted with one or more F atoms, or polyoxyethylene (—(CH2CH2O)n—H and Rb is H, C1-C12 alkyl, aralkyl, or C1-C12 alkoxy. Ar is a phenyl or naphthalene ring, optionally substituted with Rc or CO2Ph. Any of the phenyl or naphthalene rings is substituted with Rc which is H, C1-C12 alkyl, or C1-C12 alkoxy, and Rd is H or Me. X is halogen, bicarbonate (HCO3−), carbonate, bisulfate (HSO4−), bisulfite (HSO3−), methane sulfonate (MeSO3−). triethyl borohydride (Et3BH−) or a C1-C6 carboxylate. The ratio of x:y is from about 99:1 to about 1:99.

This application discloses a crystal form of an acid addition salt of an ATR inhibitor, its preparation method, and its uses. The crystal form of the acid addition salt includes at least one of the hydrogen sulfate and methanesulfonate crystal forms of the compound shown in formula (I). The crystal form of the acid addition salt of this application has advantages such as strong preparation stability, high solubility, and low hygroscopicity, making it more suitable for formulation preparation. (I)

The invention relates to a salt derivative of (R)-6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1, 2, 4-oxadiazol-3-yl) ethyl) quinazoline-4-amine, in particular to a salt derivative of (R)-6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1, 2, 4-oxadiazol-3-yl) ethyl) quinazoline-4-amine, and a salt derivative of (R)-6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1, 2, 4-oxadiazol-3-yl) ethyl) quinazoline-4-amine. The present invention relates to mesylate and ethanesulfonate salts of 2, 4-oxadiazol-3-yl) ethyl) quinazolin-4-amine, pharmaceutical compositions containing such salts, and therapeutic uses thereof. The salts of the invention are useful in the treatment of diseases or conditions associated with respiratory diseases, in particular chronic cough.

The present invention belongs to the technical field of chemical medicines. Disclosed are a salt form of a PARP inhibitor-fused heterocyclic deuterated compound, and a preparation method therefor and the use thereof. Provided in the present invention are various salt forms of a compound of formula (1), and a preparation method therefor and the use thereof. The present invention provides support for dosage form study by means of studying various salt forms of the compound, such as fumarate, tartrate, various sulfonates such as 2-naphthalenesulfonate, p-toluenesulfonate and methanesulfonate, and saccharin co-crystal, and studying crystal forms of each salt form, thereby more effectively preventing / treating PARP-related diseases, and meeting different clinical medication requirements.

The present invention relates to a cyanide-free silver plating bath composition comprising: silver methanesulfonate; a chelating agent selected from hydantoin, one of its derivatives, or a mixture thereof; a brightener selected from polyethyleneimine and bipyridine; a pH regulator selected from potassium or sodium hydroxide and water; the pH of the composition being between 8.5 and 13.5 and its electrolytic conductivity being greater than or equal to 10 mS / cm, characterized in that the composition does not comprise any brighteners other than the one selected from polyethyleneimine and bipyridine. It further relates to a method for preparing this composition, the use of this composition for the electrolytic deposition of silver onto a metallic substrate, and a method for electrolytic silver deposition using this composition.

Provided are a free base or pharmaceutically acceptable salt of a pyrazoloquinazoline compound of formula (I), which can be used as a PLK1 inhibitor, optionally in a crystalline form, and a solvate or hydrate thereof, wherein the pharmaceutically acceptable salt comprises a hydrochloride, sulfate, phosphate, maleate, fumarate, L-tartrate, citrate, L-aspartate, hippurate, L-glutamate, L-malate, adipate, glutarate, p-toluenesulfonate, and methanesulfonate of the pyrazoloquinazoline compound of formula (I), and also provided is a pharmaceutical composition comprising same, and a use thereof in the treatment of diseases and conditions caused by dysregulated activity of PLK1 and / or diseases and conditions related to PLK1, such as cancer.

Disclosed in the present invention are a crystal form of a tetrahydroisoquinoline compound and a use thereof. The present invention provides methanesulfonate crystal form A, p-toluenesulfonate crystal form A, p-toluenesulfonate crystal form B, and p-toluenesulfonate crystal form E of a compound represented by formula (I). The crystal form of the present invention has the advantages such as high purity, strong stability, high solubility, reproducible preparation, and excellent performance. The crystal form of the present invention exhibits significantly higher solubility in water, fasted-state simulated intestinal fluid, and simulated gastric fluid compared to a free base. In the pharmacokinetic study in rats, the systemic exposure dosage of the crystal form of the present invention is significantly superior to that of the free base, and the overall pharmacokinetic property is unexpectedly improved.

The present disclosure provides a novel salt of 5-chloro-2-fluoro-4-((4-fluoro-2-(methyl(2-(methylamino)ethyl)amino)phenyl)amino)-N-(thiazol-4-yl)benzenesulfonamide and a method for preparing the same. The mesylate salt of 5-chloro-2-fluoro-4-((4-fluoro-2-(methyl(2-(methylamino)ethyl)amino)phenyl)amino)-N-(thiazol-4-yl)benzenesulfonamide, which may be prepared using methanesulfonic acid and, without wishing to be bound by theory, can exhibit reduced hygroscopicity and improved physicochemical stability and solubility. In some aspects, the present disclosure provides a pharmaceutical composition for preventing or treating a sodium channel blocker-related disease, comprising the mesylate salt of 5-chloro-2-fluoro-4-((4-fluoro-2-(methyl(2-(methylamino)ethyl)amino)phenyl)amino)-N-(thiazol-4-yl)benzenesulfonamide.

Disclosed are a salt (mesylate salt) of methanesulfonic acid and a triazolopyrazine derivative of formula (1), pharmaceutical compositions thereof, methods of making the salt, and therapeutic use thereof:

The invention discloses a compound applied to semiconductor chip etching and a preparation method thereof, and the preparation method comprises the following steps: under shielding gas, uniformly mixing 4-tert-butylphenyltetramethylene sulfonium mesylate, 2-(((3r, 5r, 7r)-adamantane-1-carbonyl) oxy)-3, 3, 3-trifluoro-2-(trifluoromethyl) propane-1-sodium sulfonate, an organic solvent and ultrapure water, and stirring uniformly to obtain a mixture A of 4-tert-butylphenyltetramethylene sulfonium mesylate and 2-(((3r, 5r, 7r)-adamantane-1-carbonyl) oxy)-3, 3, 3-trifluoro-2-(trifluoromethyl) propane-1-sodium sulfonate; the preparation method comprises the following steps: adding 2-(4-tert-butylphenyltetramethylene sulfonium)-3, 3, 3, 3-trifluoro-2-(trifluoromethyl) propane-1-sulfonate into a reaction kettle, carrying out stirring and heating reaction, and after the reaction is finished, carrying out post-treatment to obtain the 4-tert-butylphenyltetramethylene sulfonium 2-(((3r, 5r, 7r)-adamantane-1-carbonyl) oxy)-3, 3, 3-trifluoro-2-(trifluoromethyl) propane-1-sulfonate. The preparation method disclosed by the invention is simple, the reaction system is green and environment-friendly, the selectivity is good, the total preparation cost is low, and the yield is high.

The invention relates to a green synthesis method of ethyl m-aminobenzoate mesylate, which comprises the following steps: carrying out catalytic hydrogenation or continuous hydrogenation reduction on m-nitrobenzoic acid in an ethanol solvent to obtain an ethanol solution of m-aminobenzoic acid, and adding methanesulfonic acid to react to obtain the ethyl m-aminobenzoate mesylate in one step. The method has the advantages of high atom economy, simple synthesis method, simple post-treatment, greenness, no pollution and the like, and a simple, convenient and efficient thought and method are provided for large-scale industrial preparation of the ethyl m-aminobenzoate mesylate.

The invention belongs to the technical field of chemical synthesis, and particularly relates to a preparation method of a rucotinib phosphate intermediate 3-cyclopentyl acrylonitrile. The method comprises the following steps: taking chlorocyclopentane as an initial raw material, reacting with magnesium chips to prepare a Grignard reagent cyclopentylmagnesium chloride, reacting with N, N-dimethylformamide to generate cyclopentylformaldehyde, carrying out addition reaction with sodium hydrogen sulfite to generate alpha-hydroxyl-cyclohexane methanesulfonic acid sodium salt, and carrying out reaction with sodium hydrogen sulfite to obtain the cyclopentylmagnesium chloride-alpha-hydroxyl-cyclohexane methanesulfonic acid sodium salt-alpha-hydroxyl-cyclohexane methanesulfonic acid sodium salt. And reacting the 3-cyclopentyl acrylonitrile with diethyl cyanomethylphosphonate to generate the 3-cyclopentyl acrylonitrile. The method has the advantages of simple synthetic route, convenience in operation, low cost, small amount of three wastes, environment friendliness and high product purity, and is more suitable for industrial mass production.